Dr.POULOMI DAS

Abstract

Introduction : Bevacizumab is much cheaper compared to ranibizumab. If only both drugs showed similar outcome in Diabetic macular edema treatment, than it will be a much less burden for patients. Here we have conducted a study on manipuri population of north eastern state of India.

Study Design : Randomised clinical trial done on 40 eyes of patients having diabetic macular edema. 20 eyes received 1.25 mg of bevacizumab and 20 eyes 0.5 mg of ranibizumab. All patients evaluated for minimum of 6 months period on regular intervals and their outcome measured with SD OCT values. At the end of study both groups showed similar outcome with no statistically significant difference between them.

Conclusion: Based on our study at least the north eastern population of India showed no difference in outcome measurement between the two drugs. In DME, bevacizumab can easily be used as a first line of drug and reduce the burden on patient in a significant amount.